AU2019331652B2 - Folate preparations - Google Patents

Folate preparations Download PDF

Info

Publication number
AU2019331652B2
AU2019331652B2 AU2019331652A AU2019331652A AU2019331652B2 AU 2019331652 B2 AU2019331652 B2 AU 2019331652B2 AU 2019331652 A AU2019331652 A AU 2019331652A AU 2019331652 A AU2019331652 A AU 2019331652A AU 2019331652 B2 AU2019331652 B2 AU 2019331652B2
Authority
AU
Australia
Prior art keywords
amount
range
preparation
vitamin
folate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019331652A
Other languages
English (en)
Other versions
AU2019331652A1 (en
Inventor
Josef Flammer
Martin Ulmann
Gerd WIESLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aprofol AG
Original Assignee
Aprofol AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aprofol AG filed Critical Aprofol AG
Publication of AU2019331652A1 publication Critical patent/AU2019331652A1/en
Application granted granted Critical
Publication of AU2019331652B2 publication Critical patent/AU2019331652B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065Diphenyl-substituted acyclic alcohols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51Thiamines, e.g. vitamin B1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • A61K31/714Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/04Sulfur, selenium or tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/34Copper; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/752Citrus, e.g. lime, orange or lemon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2019331652A 2018-08-29 2019-08-29 Folate preparations Active AU2019331652B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18191572.9 2018-08-29
EP18191572.9A EP3616700A1 (en) 2018-08-29 2018-08-29 Folate preparations for use in the treatment of eye diseases
PCT/EP2019/073118 WO2020043840A1 (en) 2018-08-29 2019-08-29 Folate preparations

Publications (2)

Publication Number Publication Date
AU2019331652A1 AU2019331652A1 (en) 2021-03-18
AU2019331652B2 true AU2019331652B2 (en) 2025-01-23

Family

ID=63449300

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019331652A Active AU2019331652B2 (en) 2018-08-29 2019-08-29 Folate preparations

Country Status (7)

Country Link
US (1) US12048702B2 (https=)
EP (2) EP3616700A1 (https=)
JP (1) JP7649962B2 (https=)
CN (1) CN112672745A (https=)
AU (1) AU2019331652B2 (https=)
CA (1) CA3110285A1 (https=)
WO (1) WO2020043840A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3461826A1 (en) * 2017-09-29 2019-04-03 Aprofol AG Multifunctional folate salts
EP3646873A1 (en) * 2018-10-31 2020-05-06 Aprofol AG Folate salts
EP3875094A1 (en) * 2020-03-02 2021-09-08 Aprofol AG Folate preparations for the treatment of ocular diseases
CN117561065A (zh) * 2021-06-24 2024-02-13 连云港金康和信药业有限公司 叶酸类衍生物在制备治疗隐形眼镜不适及干眼症药物的应用
GB202302379D0 (en) * 2023-02-20 2023-04-05 Upl Mauritius Ltd Agrochemical composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087479A1 (en) * 2001-04-30 2004-05-06 Sosnowski Robert E. Composition and method for reducing the risk or progression of cardiovascular, glaucoma, tardive dyskinesia and other diseases
EP1962618A2 (en) * 2005-12-20 2008-09-03 Alcon Research, Ltd. Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
US20080113900A1 (en) 2006-09-22 2008-05-15 Brasch Nicola E Pharmaceutical compositions and therapeutic applications for the use of a synthetic vitamin B12 derivative, glutathionylcobalamin
WO2011163301A1 (en) 2010-06-25 2011-12-29 Global Healthcare Focus, Llc Methods of treating optic disorders
TN2010000566A1 (en) 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
EP2799061A1 (en) * 2013-04-30 2014-11-05 Aprofol AG Stable high dose pharmaceutical composition containing folates
DE202015105351U1 (de) * 2015-10-09 2016-01-07 Apotheke am Schlossplatz Inh. Mario Ganster e.K. Diätetische Zusammensetzung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Prevent Glaucoma with a Folate Supplement", BOTTOM LINE HEALTH, 24 July 2014, https://bottomlineinc.com/health/glaucoma/prevent-glaucoma-with-a-folate-supplement *
CRAIG J BROWN: "Preservation of retinal structure and function after cilioretinal artery occlusion: a case report", International Medical Case Reports Journal, 2016, pgs. 29-34. DOI: 10.2147/IMCRJ.S96858 *
GIACONI ET AL: "The Association of Consumption of Fruits/Vegetables With Decreased Risk of Glaucoma Among Older African-American Women in the Study of Osteoporotic Fractures", AM J OPHTHALMOL, 2012, vol. 154, no. 4, pgs. 635-644. *
KANG JAE H ET AL: "A Prospective Study of Folate, Vitamin B-6, and Vitamin B-12 Intake in Relation to Exfoliation Glaucoma or Suspected Exfoliation Glaucoma", JAMA OPHTHALMOLOGY, 2014, vol. 132, no. 5, pgs. 549-559 *
SMOLEK MICHAEL K ET AL: "Intervention with vitamins in patients with nonproliferative diabetic retinopathy: a pilot study", CLINICAL OPHTHALMOLOGY, 2013, vol. 7, 2013, pgs. 1451-1458. *

Also Published As

Publication number Publication date
JP7649962B2 (ja) 2025-03-24
AU2019331652A1 (en) 2021-03-18
US20210308139A1 (en) 2021-10-07
US12048702B2 (en) 2024-07-30
WO2020043840A1 (en) 2020-03-05
EP3616700A1 (en) 2020-03-04
CA3110285A1 (en) 2020-03-05
EP3843744A1 (en) 2021-07-07
JP2021535131A (ja) 2021-12-16
CN112672745A (zh) 2021-04-16

Similar Documents

Publication Publication Date Title
AU2019331652B2 (en) Folate preparations
US6299896B1 (en) Multi-vitamin and mineral supplement
US6361800B1 (en) Multi-vitamin and mineral supplement
US12121537B2 (en) Dietary supplements
EP1383399B1 (en) Nutritional supplement to treat macular degeneration
US8197854B2 (en) Nutritional supplement for use under physiologically stressful conditions
US6207190B1 (en) Dosage forms for the treatment of the chronic glaucomas
CN101180062B (zh) 防治糖尿病的复方制剂
US20140106028A1 (en) Methods and kits for co-administration of nutritional supplements
US20090017167A1 (en) Mixture and beverage made therefrom for protecting cellular hydration
CN101330840A (zh) 用于抑制黄斑变性进展和促进健康视觉的组合物和方法
US10881638B2 (en) Eye health composition
JP2021535131A5 (https=)
US20130004570A1 (en) Nutritional supplement for use under physiologically stressful conditions
AU2021230087B2 (en) Folate preparations for the treatment of ocular diseases
EP1932542A1 (en) Antioxidant composition and its use in diabetes
Zhang et al. Nonprescribed Systemic Drugs and Therapies
Ghorayeb et al. 24 Chapter Vitamins and Supplements
Fuller The role of nutritional supplements in prevention, control and treatment of ocular degeneration
FARER How to Maintain or Even Improve Your Vision as You Age
US20180353530A1 (en) Combination Therapeutic Agent For The Treatment Of Macular Degeneration

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)